Back to search results

Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL

Abroad (travel likely)RecruitingPHASE2

Conditions

Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma (SLL)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Massachusetts General Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Jacob Soumerai, MD) · jsoumerai@mgh.harvard.edu

  • Memorial Sloan Kettering Cancer Center, New York, New York, United States

    Contact: Study coordinator (Andew D Zelenetz, MD, PhD) · zeleneta@mskcc.org · 212-639-2656
Study leads

  • Jacob Soumerai, MD

    Principal Investigator

    Massachusetts General Hospital

View source on ClinicalTrials.gov(opens in a new tab)